Introduction
(2) (Hargrave et al., 1991) , TIBO (3) (Pauwels et al., 1990) , pyridinones (4) (Goldman et al., 1991) , PBO (5) (Campiani et al., 1996 (Campiani et al., , 1999a and trovirdine (6) (Ahgren et al., 1995; Bell et al., 1995; Cantrell et al., 1996) . Herein we report the synthesis and biological evaluation as NNRTIs of a series of thiourea derivatives structurally related to trovirdine. The general formulae of the newly investigated compounds are given in Figure 2 . Several of the new analogues feature a quinoxaline nucleus (or a different heteroaromatic system) linked to the pyridylthiourea through an ethyl spacer; they showed potent RT inhibitory activity and proved effective against HIV-1 replication in T4 lymphocytes. 6-FQXPT (23f) (N-[2-(6-fluoro-4oxopyrrolo[1,2-a]quinoxalin-5-yl)ethyl]-N′-[2-(5-bromopyridyl)]thiourea was the most potent antiviral agent of the new series. This compound inhibits wild-type RT and several mutant RTs containing the single amino acid substitutions L100I, K103N, V106A, Y181I and Y188L. Cell-based assays indicated that QXPTs are among the most potent NNRTIs so far described, with weak to moderate cytotoxicity. A preliminary pharmacokinetic study is included.
Material and Methods: Chemistry
Melting points were determined using an Electrothermal 8103 apparatus and are uncorrected. IR spectra were taken with Perkin-Elmer 398 and FT 1600 spectrophotometers. 1 H NMR spectra were recorded on a Bruker 200 MHz spectrometer with TMS as the internal standard; the values of the chemical shifts (δ) are given in p.p.m. and coupling constants (J) in Hz. All reactions were carried out under argon atmosphere. Progress of the reaction was monitored by TLC on silica gel plates (Riedel-de-Haen). Merck silica gel (Kieselgel 60) was used for chromatography (70-230 mesh) and flash chromatography (230-400 mesh) columns. Extracts were dried over MgSO 4 , and solvents were removed under reduced pressure. Elemental analyses were performed on a Perkin-Elmer 240C elemental analyser and the results are within ±0.4% of theoretical values. Yields refer to purified products and are not optimized.
N- ethenyl)]-N′-[2-(5chloropyridyl)]urea (8) 3,4-Dimethoxycinnamic acid 7 (500 mg, 2.40 mmol) was dissolved in a mixture of triethylamine (334 µl, 2.40 mmol) and 6 ml of anhydrous tetrahydrofuran. DPPA (517 µl, 2.40 mmol) was added and the mixture was heated at 50°C for 1 h with stirring. The solvent was removed under vacuum and the residue was partitioned between water and dichloromethane. The organic layer was washed with brine, dried and evaporated. The residue was dissolved in anhydrous benzene (8 ml) and heated at reflux until N 2 evolution ceased. The solvent was removed, the residue dissolved in acetonitrile (5 ml) and 2-amino-5-chloropyridine (308 mg, 2.40 mmol) was added. The reaction mixture was stirred at room temperature for 1 h and the resulting solid was collected by filtration through a sintered glass filter, washed with acetonitrile and recrystallized from ethyl acetate-dichloromethane to afford 8 (440 mg) as colourless prisms (78% , 4.83; N 12.59. Found: C, 57.58; H, 4.91; N, 12.76. N-(2-Hydroxyethyl)-2,3-pyridinedicarboximide (11)
To 2,3-pyridinedicarboxylic anhydride 10 (1.0 g, 6.7 mmol) dissolved in dry THF (35 ml) was added a solution of ethanolamine (409 mg, 534 µl, 6.7 mmol) in dry THF (8 ml). The reaction mixture was stirred overnight and then hexane (40 ml) was added. The resulting precipitate was separated by filtration and washed with dry ether. The solid residue was suspended in dry toluene (37 ml), ZnCl 2 was added (913 mg, 6.7 mmol) and the mixture was heated at 80°C. After addition of a solution of HMDS (2.54 ml, 12.0 mmol) in dry toluene (5 ml) in portions over 30 min, the reaction mixture was refluxed overnight and concentrated under reduced pressure to give a solid, which was washed with a 0.5 M solution of citric acid and extracted with ethyl acetate (3x25 ml). The combined organic layers were then washed with saturated NaHCO 3 solution, dried and concentrated to afford a residue that was recrystallized (ethyl acetate and hexane, 1:1) to give 11 (510 mg) as white prisms (40% , 4.20; N 14.58. Found: C, 56.43; H, 3.99; N, 14.34. N-(2-Azidoethyl)-3,4-pyridinedicarboximide (12a)
To a suspension of sodium hydride (160 mg, 6.75 mmol) in anhydrous DMF (15 ml), 3,4-pyridinedicarboximide 9 (1.0 g, 6.75 mmol) was added. The reaction mixture was stirred at room temperature for 2 h and then tosylethylazide (1.6 g, 6.75 mmol) was added. After stirring for 48 h at 80°C, crushed ice was added and the resulting precipitate collected by filtration under vacuum. C, 49.77; H, 3.25; N, 32.25. Found: C, 50.07; H, 2.92; N, 32.11. N-(2-Azidoethyl)-2,3-pyridinedicarboximide (12b)
A solution of 11 (500 mg, 2.6 mmol) in anhydrous CH 2 Cl 2 was cooled to 0°C, and dry TEA (720 µl, 5.2 mmol) and methansolphonylchloride (400 µl, 5.2 mmol) were added. After 1 h stirring at 0°C the reaction mixture was quenched with water (1 ml) and extracted with dichloromethane. 189, 175, 161, 133, 106 (100) . Anal. calcd for C 9 H 7 N 5 O 2 : C, 49.77; H, 3.25; N, 32.25. Found: C, 49.94; H, 3.16; N, 31.98. General procedure for the synthesis of thioureas 14a-b
This procedure is illustrated for the synthesis of N-[2-(3,4pyridinedicarboximido)ethyl]-N′-[2-(5-bromopyridyl)]thiourea (14a). To a solution of azide 12a (100 mg, 0.46 mmol) in dioxane and water (10:1, 2 ml), triphenylphosphine (120 mg, 0.46 mmol) and trifluoroacetic acid (0.35 ml) were added. The solution was refluxed for 60 min and then diluted with water. The aqueous phase was washed with ethyl acetate and evaporated to yield the amine derivative 13a as trifluoroacetate salt, which was used without further purification. The amine 13a (165 mg, 0.46 mmol) was dissolved in dry THF (2 ml) and 2-(5-bromopyridyl)isothiocyanate (86 mg, 0.43 mmol) and anhydrous TEA (630 µl, 4.6 mmol) were added. The reaction mixture was stirred at room temperature overnight. The solvent was removed under vacuum and the solid residue was purified by flash chromatography (ethyl acetate and n-hexane, 1:1 as eluant) to afford 14a as white amorphous solid (130 mg , 44.35; H, 2.98; N, 17.24. Found: C, 43.97; H, 3.19; N, 17.36 .
Starting from 12b the title compound was obtained following an identical procedure as for 14a. After recrystallization, 14b was obtained as colourless prisms (75% , 44.35; H, 2.98; N, 17.24. Found: C, 44.41; H, 2.85; N, 16 .88.
1-(2-Azidoethyl)quinoxalin-2(1H)-one (16a)
To a suspension of sodium hydride (69.7 mg, 2.81 mmol) in anhydrous DMF (10 ml) the lactam 15a (410 mg, 2.81 mmol) was added in one portion. The reaction mixture was stirred at room temperature for 2 h and then tosylethylazide (667 mg, 2.81 mmol) was added. After 24 h of stirring at 80°C the solvent was removed under vacuum and the residue was dissolved in ethyl acetate. The organic phase was washed with brine, dried and concentrated. The residue was purified by flash chromatography (ethyl acetate and hexane, 1:1, as eluant) to afford 16a as a yellow solid. After recrystallization the N-ethylazide 16a was obtained as colourless prisms (157 mg , 4.22; N, 32.54. Found: C, 56.03; H, 4.46; N, 32.69. 5-(Azidoethyl)-6,7-dihydropyrrolo[1,2a]pyrazin-4(5H)-one (16b)
Starting from 15b, the title compound was obtained following an identical procedure as for 16a (30%): m.p. 86-87°C. IR (nujol) 1615 cm -1 ; 1 H NMR (CDCl 3 ) δ 3.50-3.70 (m, 4H), 3.77 (m, 2H), 4.13 (m, 2H), 6.20 (m, 1H), 6.71 (m, 1H), 6.91 (m, 1H). Anal. calcd for C 9 H 11 N 5 O: C, 52.67; H, 5.40; N, 34.13. Found: C, 52.74; H, 5.40; N, 33.95. 
1-(2-Aminoethyl)quinoxalyn-2(1H)-one (17a)
The azide 16a (130 mg, 0.6 mmol) was suspended in dry, freshly distilled methanol (4 ml). The flask was purged with argon and propane-1,3-dithiol (180 µl, 1.8 mmol) and anhydrous triethylamine (250 µl, 1.8 mmol) was added. The solution was stirred at room temperature for 24 h, the solvent was then removed under vacuum, and the residue was purified by flash chromatography (elution with methanol and triethylamine, 9:1) to obtain 17a (100 mg) as a white solid. The amine was used in the next step without further purification (89%). IR (nujol) 1620 cm -1 ; 1 
General procedure for the synthesis of 18a-b
This procedure is described for the preparation of N-[2-(2-oxoquinoxalin-1-yl)ethyl]-N′-[2-(5-bromopyridyl)]thiourea (18a). To a solution of 17a (94.5 mg, 0.5 mmol) in anhydrous acetonitrile (2 ml) 2-(5-bromopyridyl)isothiocyanate (107 mg, 0.5 mmol) was added, and the reaction mixture stirred at room temperature overnight. The resulting precipitate was collected by filtration through a sintered glass filter and washed with another portion of acetonitrile to afford 18a (165 mg) as a colourless solid , 4.45; N 19.33. Found: C, 50.02; H, 4.38; N, 19.15. General procedure for the synthesis of N-alkylated quinoxalinones 20a-e and a typical example of O-alkylated quinoxaline 21
This procedure is illustrated for the preparation of 5-(2azidoethyl)-7,8-dimethylpyrrolo[1,2-a]quinoxalin-4(5H)one (20a) and 4-(2-azidoethoxy)-7,8-dimethylpyrrolo [1,2-a]quinoxaline (21). To a suspension of sodium hydride (69.7 mg, 2.81 mmol) in anhydrous DMF (10 ml) the piroloquinoxaline 19a (0.6 g, 2.81 mmol) was added in one portion. The reaction mixture was stirred at room temperature for 2 h and then tosylethylazide (667 mg, 2.81 mmol) was added. After 24 h of stirring at 80°C the solvent was removed under vacuum and the residue was dissolved in ethyl acetate. The organic phase was washed with brine, dried and concentrated. The residue was purified by flash chromatography (ethyl acetate and hexane, 1:2, as eluant) to afford 21 and 20a as white solids (compound 21 eluted first). After recrystallization (ethyl acetate and hexane, 1:3) the N-ethylazide 20a was obtained as colourless prisms. 20a ( , 5.37; N, 24.89. Found: C, 64.31; H, 5.23; N, 24 .68.
5-
Starting from 19b, the title compound was obtained following an identical procedure as for 20a. After recrystallization, the title compound was obtained as pale yellow prisms ( 
General procedure for the synthesis of the aminoethyl derivatives 22a-e
This procedure is illustrated for the preparation of 5-(2aminoethyl)-7,8-dimethylpyrrolo[1,2-a]quinoxalin-4(5-H)-one (22a). The azide 20a (112 mg, 0.4 mmol) was suspended in dry, freshly distilled methanol (4 ml). The flask was purged with argon and propane-1,3-dithiol-(120 µl, 1.2 mmol) and anhydrous triethylamine (166 µl, 1.2 mmol) was added. The solution was stirred at room temperature for 24 h; the solvent was then removed under vacuum and the residue was purified by flash chromato-graphy (elution with methanol and triethylamine, 9:1) to obtain 22a as a white solid. The amine was used in the next step without further purification (90% 
5-
Similarly to 22a, the amine 22b was prepared starting from 20b. General procedure for the synthesis of QXPTs 23a-f
This procedure is described for the preparation of N-[2-
. To a solution of aminoethylquinoxalinone 22a (127 mg, 0.5 mmol) in anhydrous THF (2 ml), 2-(5-bromopyridyl)isothiocyanate (107 mg, 0.5 mmol) was added and the reaction mixture was stirred at room temperature for 1 h. The resulting precipitate was collected by filtration through a sintered glass filter and washed with another portion of THF. Recrystallization from THF gave 23a (211 mg , 4.29; N, 14.89. Found: C, 53.74; H, 4.14; N, 15.20 .
Starting from 22b the title compound was prepared following the procedure described for the synthesis of 23a (reaction time 3 h). The title compound was recrystallized from MeOH (94%) OS: C, 52.64; H, 3.98; N, 15.35. Found: C, 52.48; H, 4.05; N, 15.53 .
Starting from 22c the title compound was prepared following an identical procedure as for the synthesis of 23a (reaction time 2 h). The title compound was recrystallized from MeOH (95%) 
Material and Methods: Virology
HIV-1 RT activity assay RT RNA-dependent DNA polymerase activity was assayed as follows: a final volume of 25 µl contained reaction buffer (50 mM Tris-HCl pH 7.5, 1 mM DTT, 0.2 mg/ml BSA, 4% glycerol), 10 mM MgCl 2 , 0.5 µg poly(rA).oligo(dT) 10:1 (0.3 µM 3′-OH ends), 10 µM [3H]dTTP (1 Ci/mmol) and 2-4 nM RT. Reactions were incubated at 37°C for the indicated time. Aliquots of 20 µl were then spotted on glass fibre GF/C filters which were immediately immersed in ice-cold 5% TCA. Filters were washed twice in ice-cold 5% TCA and once in ethanol for 5 min, dried and acid-precipitable radioactivity was quantified by scintillation counting (Maga et al., 1997) .
Reactions were performed under the conditions described for the HIV-1 RT activity assay. Incorporation of radioactive dTTP into poly(rA).oligo(dT) was monitored in the presence of increasing amounts of the inhibitor to be tested. Data were then plotted according to Lineweaver-Burke and Dixon. For K i determinations an interval of inhibitor concentrations between 0.2 K i and 5 K i was used. Experiments were carried out in triplicate. Experimental errors (±SD) were ≤10%.
In vitro anti-HIV activity and cell culture assay Test in the CEM cell line. Testing was performed by the US National Cancer Institute's Developmental Therapeutics Program, AIDS Antiviral Screening Program. The ability of the test compounds to protect HIV-1-infected T4 lymphocytes (CEM cells) from cell death was determined following the reported procedure (Weislow et al., 1989) . All compounds were compared with a positive (zidovudine-treated) control performed at the same time under identical conditions.
Other cell lines. Mature macrophages were obtained by incubating, in 48-well plates (Costar), 10 6 PBMC per ml of complete medium (containing RPMI-1640, 100 units/ml penicillin, 100 mg/ml streptomycin, 0.3 mg/ml L-glutamine and 20% heat-inactivated FCS). After 7 days of incubation in 5% CO 2 at 37°C, non-adherent cells (lymphocytes) were removed by extensive washing. Using this method, the yield, after removal of the non-adherent cells, was 10 5 macrophages per well. Further details of this procedure are described elsewhere (Perno et al., 1988) . Macrophages obtained with this method are >95 % pure as detected by non-specific esterase activity. C8166 is a CD4 + T cell line containing an HTLV-I genome of which only the tat gene is expressed (Sodroski et al., 1984) .
Virus.
A laboratory lymphocyte-tropic strain of HIV-1 IIIB was used to infect C8166 cells. A laboratory monocytetropic strain of HIV-1 (HTLV-III Ba-l, also called HIV-Ba-l) was used to infect macrophages. Details of the characteristics of the laboratory strains are reported elsewhere (Gartner et al., 1986; Popovic et al., 1984) . The source of the HIV-1 laboratory lymphocyte-tropic and monocyte-tropic strains were, respectively, the supernatants of H9/IIIB (H9) cultures (H9 is a CD4 + T cell line persistently infected with HIV-1) and the supernatants of infected macrophage cultures. Titration to determine the infectivity was performed in human macrophages as previously described. The titre of the virus stocks, expressed as 50% tissue culture infectious dose (TCID 50 ), was determined as previously described (Karber, 1931) .
Toxicity. The toxicity of the compounds in C8166 cells was evaluated with a procedure involving a colorimetric assay (MTT assay) that monitors the ability of viable cells to reduce 3-(4-dimethylthiazol-2-yl)-2,5-diphenyltetrazolum bromide (MTT) to a blue formazan product, which can be measured spectrophotometrically. Details of this methods are described elsewhere (Bergamini et al., 1992; Pauwels et al., 1988) .
Assay of antiviral activity. For evaluation of antiviral activity in acutely infected C8166 cultures, the cells were distributed into 15 ml polyethylene tubes at a concentration of 90x10 3 cells/ml and exposed to 100 TCID 50 of HIV in the presence or absence of antiviral compounds. After 2 h incubation in 5% CO 2 at 37°C, the cells were washed twice in PBS and inoculated in each well of a 96-well plate (Falcon 3042) at a concentration of 35x10 3 cells per 200 µl of complete medium. The cells were subsequently cultured in the presence of the same concentrations of drugs as before for 5 days. The antiviral activity of the compounds was assessed by quantifying the HIV-induced cytopathogenicity by the MTT assay. The percentage protection from CPE achieved by each compound in HIV-infected cells measured by the MTT assay was calculated by the following formula: (A T ) HIV -(A C ) HIV /(A C ) mock -(A C ) HIV , expressed as a percentage, where (A T ) HIV is the absorbance measured for a given concentration of compound in HIVinfected cells; (A C ) HIV is the absorbance measured for the control untreated HIV-infected cells; and (A C ) mock is the absorbance measured for the control untreated mockinfected cells. The absorbance at 490/650 nm was measured using a plate reader.
The assay to evaluate anti-HIV drug efficacy in acutely infected mature macrophages was performed according to Karber (1931) .
Immunofluorescence virus binding assay. Calculation of the 50% effective dose (ED 50 ) and 50% inhibitory con-Novel quinoxalinylethylpyridylthiourea antivirals centration IC 50 was performed from pooled values in the effective dynamic range of the antiviral and toxicity assays (5-95%) using the median effect equation as previously described (Chou, 1976) .
Toxicity tests
Cell lines. All cell lines were obtained from the ATCC. The cells were cultured in RPMI-1640 supplemented with 5% FCS, 0.1 mM glutamine, 1% penicillin and streptomycin. Cells were grown in Nunc clone plastic bottles (Tednune, Roskilde, Denmark) and split twice weekly at different cell densities according to standard procedure. 3T3 cells were grown as monolayers and were split using trypsin. Peripheral blood mononuclear cells (PBMC) were separated from heparinized whole blood obtained from a healthy donor on a Fycoll-Hypaque gradient as previously described (D'Atri et al., 1986) . PBMC thus obtained were washed twice with RPMI-1640 supplemented with 10% FCS, glutamine and antibiotics, suspended at 200000 viable cells/ml in medium containing 5 µg/ml phytohaemagglutinin as mitogen (Sigma) and used in toxicity tests.
Chemicals. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide] was purchased from Aldrich. It was dissolved at a concentration of 5 mg/ml in sterile PBS at room temperature and the solution was further sterilized by filtration and stored at 4°C in a dark bottle. SDS was obtained from Sigma. Lysis buffer was prepared as follows: 20% (w/v) of SDS was dissolved at 37°C in a solution of 50% DMF and 50% demineralized water; pH was adjusted to 4.7 by adding 2.5% of 80% acetic acid and 2.5% 1 M HCl solution.
Toxicity experiments. Cells were plated at different concentrations on flat-bottom 96-well microplates (0.1 ml/well). Lymphocytes were plated out at 20000 cells/well. 3T3 cells (murine fibroblast line) were plated at 10000 cells/well. NSO cells (plasmocytoma murine cell line) were plated out at 3000 cells/well and Daudi cells (human lymphoblastoid cell line) were plated at 300 cells/well. At 12 h after plating, different concentrations of each compound were added to each well. After 48 h, the MTT assay was performed to analyse cytotoxicity of the different compounds. Some experiments were performed using confluent cells: compounds were added to the 3T3 cell monolayer 3 days after plating. Tests were then run as described above.
MTT/formazan extraction procedure. Twenty µl of the 5 mg/ml stock solution of MTT were added to each well; after 2 h of incubation at 37°C, 100 µl of the extraction buffer were added. After an overnight incubation at 37°C, the absorbances at 570 nm were measured using a Titer-Tech 96-well multiscanner, employing the extraction buffer as the blank.
Synergy calculations
The multiple drug effect analysis of Chou and Talalay (1984) was used to calculate combined drug effects. This method involves plotting dose-effect curves for each agent and for one or more multiply-diluted, fixed combinations of the agents using the 'median effect' equation: f a /f u =(D/D m )m. In this equation, D is the dose, D m is the dose required for 50% effect (50% inhibition of viral replication), f a is the fraction affected by the dose D, f u the fraction unaffected and m a coefficient signifying the sigmoidicity of the dose-effect curve. The dose-effect curve is plotted using a logarithmic conversion of this equation which determines the m and D m values. Based on the slope of the dose-effect curves, it can be decided whether the agents have mutually exclusive effects (similar mode of action) or mutually non-exclusive effects (independent mode of action). A 'combination index' (CI) is then determined using the equation:
CI=D 1 /Dx 1 +D 2 /Dx 2 +aD 1 D 2 /Dx 1 Dx 2 Dx 1 the dose of the agent 1 required to produce X% effect alone, D 1 is the dose of that agent required to produce the same X% effect in combination with D 2 . Similarly Dx 2 is the dose of the agent 2 required to produce the X% effect alone and D 2 the dose required to produce the same effect in combination. If the agents are mutually exclusive, then a is 0 (i.e. CI is the sum of two terms); if mutually non-exclusive, a is 1 (i.e. CI is the sum of three terms). If it is uncertain whether the agents act in a similar or independent manner, the formula may be solved in both ways. Values of CI less than one indicate synergy, greater than one antagonism, and equal to one additive effect.
Drug administration and plasma and brain sampling
Male CD1 mice weighing about 25 g (Charles River, Italy) were used. Procedures involving animals and their care conformed with institutional guidelines, which are in compliance with national (D.L. n. 116, G.U., Suppl. 40, 18 Febbraio 1992 , Circolare No. 8, G.U., 14 Luglio 1994 and international laws and policies (EEC Council Directive 86/609, OJ L 358,1, December 12, 1987 ; Guide for the Care and Use of Laboratory Animals, US National Research Council, 1996) . Animals received the test compounds subcutaneously, dissolved in PEG-400:ethanol:Tween 80 (60:30:10 v/v; 23f) and were euthanized by decapitation under deep anesthaesia 15, 30, 60 and 120 min after dosing. Blood samples were collected in heparinized tubes, centrifuged and the plasma was stored at -20°C. Brains were rapidly removed, blotted with paper to remove excess surface blood and stored at -20°C until analysis. Animals tolerated 23f doses with no observable discomfort.
Drug analysis
Plasma and brain concentrations of compound 23f were determined by high-performance liquid chromatography (HPLC) with UV detection (300 nm). Briefly, after addition of a chromatographically suitable internal standard to plasma (0.2 ml) and shaking with methanol, the samples were centrifuged and the extract was evaporated to dryness. The residue was dissolved in the mobile phase and injected in the HPLC column. Brain tissue was homogenized in methanol (1 g/5 ml) and centrifuged at 5000 r.p.m. for 10 min. The residue was re-suspended in 1 ml of methanol, shaken in a vortex-mixer and re-centrifuged. The combined supernatants were then processed as described for plasma. Separation was done at room temperature on a Supelcosil LC18 DB column (25 cm×4.6 mm ID, 5 µm particle size; Supelco, Bellefonte, Penn., USA), protected by a RP-18 NewGuard precolumn (Brownlee Labs Inc., Calif., USA). The mobile phase was 0.025 M ammonium acetate:methanol:propyl alcohol (36:63:1, v/v) buffered to pH 6.5 with acetic acid for the analysis of compound 23f. The mobile phases were delivered isocratically at a flow rate of 1.2 ml/min. The retention time of 23f was 16 min. The overall mean recovery, determined by comparing the peak height of 23f with those obtained after direct injection of the compounds, averaged 80-86% over the range of 0.05-1.25 µg/ml or g. Within this range the coefficients of variation (CV) were generally below 10% in both tissues. The sensitivity limit was 0.05 µg/ml or g, using 0.2 ml of plasma or approximately 200 mg of brain tissue.
Additional data
Synergistic data for 23f with zidovudine are available from the Editor-in-Chief on request.
Results

Chemistry
Syntheses were accomplished as shown schematically in Figures 3-6. The desired products 14a,b, 18a,b and 23a-f were prepared starting from the corresponding key amino intermediates 13a-b, 17a,b, and 22a-e following a similar 14a,b, 18a,b and 23a-f synthetic procedure, using 2-(5-chloro(bromo)pyridyl)isothiocyanate, in turn prepared from 2-amino-5chloro(bromo)pyridine and 1,1′-thiocarbonyldiimidazole or thiophosgene, except for compound 8 which was prepared following a different procedure (Figure 3 ). The analogue 8 was in turn prepared starting from 3,4dimethoxycinnamic acid 7 (Figure 3 ) by reaction with DPPA in the presence of triethylamine (TEA) (Campiani et al., 1993) , obtaining, after heating, an isocyanate intermediate which was transformed to 8 by means of 2-amino-5-chloropyridine. Afterwards, we decided to investigate the compounds shown in Figures 4-6 to assess the role of an heteroaromatic system linked to the ethyl spacer. Figure  4 summarizes the synthetic approach to the pyridinedicarboximidothioureas 18a,b. The azido intermediate 12a was prepared starting from the 3,4-pyridinedicarboximide 9, which was directly alkylated to 12a by the use of tosylethylazide (Carboni et al., 1987) , while 12b was obtained starting from the anhydride 10. Reaction of this latter with β-aminoethanol and successively with zinc chloride provided the N-alkylated dicarboximide 11 (Reddy et al., 1997) which, after transformation in the corresponding mesylate in the presence of TEA (Campiani et al., 1993) , was treated with sodium azide to give 12b. After examination of several reduction methods we found that treatment of azides 12a,b with triphenylphosphine and trifluoroacetic acid afforded the desired amines 13a,b as trifluoroacetate salts. Lastly, by treatment of 13a,b with 2-(5-bromopyridyl)isothiocyanate in the presence of triethylamine, the thioureas 14a,b were obtained in good yields. The effect of different heterocyclic skeletons on the anti-enzymatic activity was further investigated with the synthesis of ethylthioureas 18a,b ( Figure 5) and QXTPs 23a-f ( Figure 6 ). The analogues 18a,b bearing a quinoxalinone or a pyrrolopyrazinone system, respectively, were obtained in the following manner ( Figure 5 ). N-alkylation of 15a,b (Akira & Watanabe, 1975; Makino & Yoshioka, 1987) with tosylethylazide and sodium hydride in N,N-dimethylformamide (DMF) afforded in good yield the ethylazides 16a,b, which, after reduction to 17a,b, were transformed to 18a,b by the standard method. In order to attempt an optimization of the pharmacological properties, analogues of 18a,b were chosen for synthesis which contain additional substituted π-systems. Consequently, pyrroloquinoxalines, bearing a N-ethyl-N′-pyridylthioureic moiety, were prepared. Lactams 19a-e were prepared according to previ-©2000 International Medical Press ously described procedures (Campiani et al., 1997 (Campiani et al., , 1999b Davey et al., 1991; Prunier et al., 1997; McQuaid et al., 1992) . Alkylation of 19a-e with tosylethylazide provided a mixture of N-alkylated and O-alkylated products (20a-e and 21, as an example). Usually the O-alkylated products were obtained in 10-25% yield. Successively the azides 20a-e were reduced to amines 22a-e by the use of 1,3propanedithiol-triethylamine in methanol (Campiani et al., 1993) and transformed in thioureas 23a-f.
Anti-RT and anti-HIV-1 activity
The newly described ethylpyridylthioureas (8, 14a,b, 18a,b and 23a-f) were tested in vitro against HIV-1 wild-type RT. The whole set of compounds was also tested on a panel of RT mutants including L100I, Y181I, V106A, commonly produced upon treatment with dipyridodiazepinones, and K103N, a mutant associated with resistance to pyridones and nevirapine. The Y188L, a mutation occurring in patients treated with both nevirapine and zidovudine, was also included. Table 1 reports the K i values calculated from the above experiments. A selected set of compounds was evaluated for its ability to inhibit both wild-type HIV-1 cytopathicity in T4 cells (CEM-SS) and the formation of syncytia in C8166 cells infected with wild-type HIV-1 IIIB virus. Furthermore, the most potent QXPT analogue, 23f, was further tested on monocyte-macrophages infected with HTLV-III Ba-L (a laboratory adapted monocytotropic strain) in order to confirm its potential as an antiviral agent. A good correlation was found between anti-enzymatic activity and antiviral efficacy. MTT assays were also conducted as a measure of the cytotoxic effect of the new compounds on four different cell lines, and synergistic antiviral activity with zidovudine has been calculated for 23f, the most promising antiviral of the QXPT series. Finally, pharmacokinetic studies conducted on 6-FQXPT (23f) confirm its ability to cross the blood-brain barrier.
Discussion
The results of the anti-enzymatic assays are reported in Table 1 . The first question addressed was whether the bioactive conformation of the ethyl spacer of these new antiviral agents was of a cisoid or a transoid type. The conformation of the spacer seems to be crucial for anti-enzymatic activity. In fact, by blocking the ethylene linker in a trans configuration (8) we obtained an inactive compound, indicating that the spacer attains a cisoid conformation at the binding site level for optimum interaction. The subsequent question addressed was whether the antiviral activity and the spectrum of activity could be improved by introducing different heteroaryl moieties in place of the pyridine ring of trovirdine. As illustrated in Table 1 , the potency of inhibition of wild-type and mutated RT is strictly dependent on the nature of the heterocyclic skeleton and on the type of substituents on it. Among the bicyclic analogues (14a,b and 18a,b) when the pyridinecarboxydiimide is linked to the ethylpyridylthiourea moiety (14a,b), the activity versus wild-type and mutant RTs (L100I, K103N, V106A, Y181I and Y188L) is dependent upon the position of the nitrogen atom. In fact 14b is characterized by a higher potency and broader spectrum compared with its counterpart 14a, in which the pyridine nitrogen is more basic. Furthermore, the bicyclics 18a,b gave us the possibility to define the role played by other structural features in determining efficacy and spectrum of activity. When the fused pyrrole ring is missing (18a), the potency against wild-type RT and all the mutants of the panel, except for V106A, drops. On the other hand, the pyrrolopyrazine analogue 18b, in which the benzo-fused ring is not in place, maintains high inhibitory activity against wild-type and L100I, K103N, V106A, as well as against Y181I and Y188L mutant RT. Combining a pyrazinone ring with a fused pyrrole ring and a benzo-fused system we obtained a series of heteroaromatic derivatives 23a-f. In the quinoxaline series the potency of inhibition of RT is modulated by Figure 6 . Synthesis of QXPTs the substituents on the pyridine ring (bromine or chlorine, 23d,e) and on the benzo-fused ring (23a-c,f). Methyl groups at C-7 (23b) and at positions 7 and 8 (23a) could be accommodated into the lipophilic RT-binding pocket, 23a,b being slightly more active than 23d versus wild-type RT, while the two chlorine atoms at C-7 and C-8 of 23c confer higher potency against Y181I compared with 23a,b. Activity is also influenced by a fluorine atom at position 6 (23f). In fact, 23f is more active against wild-type RT than its unsubstituted analogue 23d, maintaining a significant potency against Y181I and Y188L mutants. Taking into account the inhibitory potency against wild-type and the other mutants, especially Y188L (Table 1) it appears that 23f (6-FQXPT) represents an interesting new generation lead for the design of further antiviral agents within this series. Selected compounds were further tested for their ability to block virus proliferation in cell lines such as CEM-SS and C8166, and in monocyte-macrophages. The results are presented in Table 2 . Among the heterocyclic analogues, those bearing the quinoxaline system (QXPTs) showed a greater antiviral activity in CEM-SS and C8166 cells. In general, when the EC 50 and IC 50 values of substituted QXPTs (23a-c,f) are compared with those of their corresponding unsubstituted analogues (23d,e) it is clear that the introduction of a fluorine atom at position 6 leads to an improvement in potency. 6-FQXPT 23f represents the most potent compound in the considered series. Furthermore, 23f was also studied on monocytemacrophages infected with HTLV-III Ba-L (Gao et al., 1994) . In this test 23f proved to be extremely potent (IC 50 16.6 µM, EC 50 0.002 µM, selectivity index 8830). Taking into account the data shown in assays using different infected cells, the fluorinated QXPT 23f turned out as the most potent antiviral agent within our series with a promising selectivity index.
Although some of these novel antiviral agents showed promising selectivity indexes in cell culture assays, 14a, 18b and 23b-f were screened in a MTT assay using murine NSO, human Daudi and murine 3T3 fibroblast cell lines, and normal human lymphocytes. 6-FQXPT 23f showed a low cytotoxicity (Table 2) .
The rapid emergence of resistance in AIDS patients has limited the monotherapy approach with any of the known and safe non-nucleoside inhibitors. Combination of two or three antiviral agents is preferred, since multidrug regimens are more effective against HIV-1 infection, with simultaneous reductions in drug dosages, toxicity and resistance. Two of the clinically preferred combinations include drugs that act on different targets in the viral life-cycle or on different receptor sites within the same viral protein (De Clercq, 1995) . To evaluate the potential of the new series of inhibitors in a multidrug approach, we investigated the synergistic antiviral activity of 23f (6-FQXPT) in combi- †The IC 50 value is the test compound concentration that results in 50% survival of uninfected untreated control CEM-SS and C8166 cells (cytotoxicity of the test drug). ‡The EC 50 value is the test compound concentration that produces 50% survival of HIV-1-infected cells relative to uninfected untreated controls (in vitro anti-HIV-1 activity). §SI, selectivity index (IC 50 /EC 50 ). ¶Blank was subtracted from A 570 . All data reported are absorbance x1000. SD (data not shown) never exceeded 5% of the mean value. Absorbances measured in the control row were: NSO, 0.125±0.015; DH 0.129±0.018; 3T3F 0.131±0.014; HL 0.114±0.01. Table 2 . Inhibition of HIV-1 infection in CEM-SS cells*, inhibition of HIV-IIIB infection in C8166 cells and cytotoxicity in NSO, Daudi and 3T3 cells and normal human lymphocytes nation with the nucleoside analogue zidovudine. 6-FQXPT proved to be able to potentiate the antiviral activity of zidovudine, and zidovudine was able to potentiate its activity. The extent of the synergistic activity was quantified according to Chou and Talalay (1984) by the calculation of the combination index (CI). 23f showed a synergistic anti-HIV-1 activity (CI<1) when tested in combination with zidovudine, notwithstanding that mutually exclusive or non-exclusive assumption formulae were used.
Because HIV-1 enters the brain and causes neurological disorders associated with AIDS dementia complex (Resnik et al., 1988) , effective antiviral agents must penetrate the blood-brain barrier and diffuse within the central nervous system (Portegies, 1995) . Early studies showed that the potent inhibitor of HIV-1 reverse transcriptase N-(2pyridylethyl)-N′-2-(5-bromopyridinyl)thiourea(LY73497) readily crosses the blood-brain barrier in rats (Ahgren et al., 1995) . Similarly, 6-FQXPT 23f, which we found to have subnanomolar potency against HIV-1 in cell culture assays, rapidly enters the mouse brain, reaching mean maximum concentrations (C max ) at the same time as in plasma, 30 min after subcutaneous dosing (20 mg/kg).
It thus appears that compounds of this type easily cross the blood-brain barrier, despite some unfavourable chemical characteristics such as molecular weight within the suggested limit for significant brain entry and the presence of potential hydrogen-bonding sites in their structure (Levin, 1980) . However, concentrations of 23f in plasma (1.4±1.3 nmol/ml; n=3) and brain (2.2±2.0 nmol/g; n=3) and their ratios were relatively low and variable. Also, these concentrations rapidly fell below the limit of quantification (<0.1 nmol/ml or g) within 2 h of dosing. This is possibly because of the rapid and extensive biotransformation of this compound. Accordingly, several putative metabolite peaks were observed in plasma (but not brain) chromatograms of 23f-treated mice, the major one (retention time 13.5 min) reaching mean concentrations similar to the parent compound, assuming that recovery from plasma and extinction coefficient are the same for the probable parent compound.
In conclusion, this investigation led to the discovery of a series of potent, broad-spectrum anti-RT agents with antiviral activity. Combining synthesis and biological evaluation, the structure-activity relationship studies brought to light a number of structural features that affect the potency and efficacy of these ethylpyridylthioureidic antiviral agents. In the QXPT series the antiviral activity depends on the substituent on the benzo-fused ring. Activity is optimum with a fluorine at position 6: 23f is a potent, new generation inhibitor of HIV-1 replication with synergistic antiviral activity with zidovudine. Although the potential of 23f as an anti-HIV drug is limited by its rapid metabolism, 23f represents a lead compound for the development of further analogues.
